The pace is picking up in several markets for arrhythmia management devices, according to a report published in January 2005 by Windhover/Medtech Insight, "US Markets for Arrhythmia Management Products." Cardiac arrhythmias currently account for approximately 20% of all chronic conditions treated by cardiologists in the US, and the product markets--which include anti-arrhythmic drugs, electrical heart stimulation devices, and surgical or transcatheter procedures that remodel the heart's electrical signal conduction pathways--are growing.
This is a clinical specialty in which devices are far more effective than drugs, and although the arrhythmia device markets...